ArticleCancers2022

Real-World Experience of Measurable Residual Disease Response and Prognosis in Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine.

Shin Yeu Ong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.